Page 36 - Influenza Report
P. 36
36 Influenza
http://amedeo.com/lit.php?id=11533192 Full text at
http://jvi.asm.org/cgi/content/full/75/19/9297?pmid=11533192
43. Govorkova EA, Rehg JE, Krauss S, et al. Lethality to ferrets of H5N1 influenza viruses
isolated from humans and poultry in 2004. J Virol 2005; 79: 2191-8. Abstract:
http://amedeo.com/lit.php?id=15681421 Full text at
http://jvi.asm.org/cgi/content/abstract/79/4/2191
44. Gürtler L. Virology of Human Influenza. In: Influenza Report. Kamps BS, Hoffmann C,
Preiser W. Flying Publisher, Wuppertal, 2006. Full text at
http://www.influenzareport.com/ir/virol.htm
45. Hatta M, Gao P, Halfmann P, Kawaoka Y. Molecular basis for high virulence of Hong
Kong H5N1 influenza A viruses. Science 2001; 293: 1840-2. Abstract:
http://amedeo.com/lit.php?id=11546875 Full text at
http://www.sciencemag.org/cgi/content/full/293/5536/1840
46. Hayden F, Klimov A, Tashiro M, et al. Neuraminidase inhibitor susceptibility network
position statement: antiviral resistance in influenza A/H5N1 viruses. Antivir Ther 2005; 10: 873-
7. Abstract: http://amedeo.com/lit.php?id=16430192
47. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor
oseltamivir to prevent influenza. N Engl J Med 1999; 341: 1336-43. Abstract:
http://amedeo.com/lit.php?id=10536125 Full text
http://content.nejm.org/cgi/content/full/341/18/1336
48. Hayden FG, Belshe R, Villanueva C, et al. Management of influenza in households: a
prospective, randomized comparison of oseltamivir treatment with or without postexposure
prophylaxis. J Infect Dis 2004; 189: 440-9. Epub 2004 Jan 26. Abstract:
http://amedeo.com/lit.php?id=14745701 Full text at
http://www.journals.uchicago.edu/JID/journal/issues/v189n3/31422/31422.html
49. Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of
influenza in families. Zanamivir Family Study Group. N Engl J Med 2000; 343: 1282-9.
Abstract: http://amedeo.com/lit.php?id=11058672 Full text at
http://content.nejm.org/cgi/content/full/343/18/1282
50. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase
inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.
N Engl J Med 1997; 337: 874-80. Abstract: http://amedeo.com/lit.php?id=9302301 Full text at
http://content.nejm.org/cgi/content/full/337/13/874
51. Hayden FG. Antiviral Resistance in Influenza Viruses Implications for Management and
Pandemic Response. N Engl J Med 2006; Volume 354:785-8. Full text at
http://content.nejm.org/cgi/content/full/354/8/785
52. Hedrick JA, Barzilai A, Behre U, et al. Zanamivir for treatment of symptomatic influenza A
and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr
Infect Dis J 2000; 19: 410-7. Abstract: http://amedeo.com/lit.php?id=10819336
53. Herlocher ML, Truscon R, Elias S, et al. Influenza viruses resistant to the antiviral drug
oseltamivir: transmission studies in ferrets. J Infect Dis 2004; 190: 1627-30. Epub 2004 Sep 28.
Abstract: http://amedeo.com/lit.php?id=15478068 Full text at
http://aac.asm.org/cgi/content/abstract/45/4/1216
54. Hien TT, Liem NT, Dung NT, et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N
Engl J Med 2004; 350: 1179-88. Abstract: http://amedeo.com/lit.php?id=14985470 Full text
at http://content.nejm.org/cgi/content/full/350/12/1179
55. Hoelscher MA, Garg S, Bangari DS, et al. Development of adenoviral-vector-based
pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet
2006; 367: 475-81. Abstract: http://amedeo.com/lit.php?id=16473124
56. Hoffmann C, Kamps BS. Clinical presentation. In: Influenza Report. Kamps BS, Hoffmann
C, Preiser W. Flying Publisher, Wuppertal, 2006a. Full text at
http://www.influenzareport.com/ir/cp.htm
57. Hoffmann C, Kamps BS. Treatment and Prophylaxis. In: Influenza Report. Kamps BS,
Hoffmann C, Preiser W. Flying Publisher, Wuppertal, 2006b. Full text at
http://www.influenzareport.com/ir/tr.htm
